- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04002882
Role of Body Fat Distribution in Metabolic and Pulmonary Decline in Cystic Fibrosis (ORBIT-CF)
Outcomes Related to Body Composition in Teens and Adults With Cystic Fibrosis (ORBIT-CF)
Nutrition and body composition, the amount of muscle and fat in the body, has a role in overall health. This study wants to learn more about how nutrition and body composition affects health outcomes like glucose tolerance and lung function in patients with cystic fibrosis (CF) who are ages 16-30 years old. 60 adolescents and young adults with CF will be recruited, and 30 volunteers without cystic fibrosis. A total of 40 of these study participants with CF will be asked to return for annual study visits for 2 years after the first visit.
The long-term goal of this study is to use the information collected to make decisions about future nutrition monitoring and interventions which help maintain optimal health for individuals with CF.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Jessica A Alvarez, PhD, RD
- Phone Number: 4047271390
- Email: jessica.alvarez@emory.edu
Study Contact Backup
- Name: Swati Zaveri, PhD
- Phone Number: 440-778-8373
- Email: swati.shital.zaveri@emory.edu
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Not yet recruiting
- University of Alabama at Birmingham (UAB)/Children's of Alabama
-
Contact:
- Michael Stalvey, MD
- Phone Number: 205-638-9107
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Emory University/Children's Hospital of Atlanta (CHOA)
-
Contact:
- Jessica Alvarez, PhD, RD
- Phone Number: 404-727-1390
- Email: jessica.alvarez@emory.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
CF inclusion criteria
- confirmed CF diagnosis based on sweat testing by pilocarpine iontophoresis and/or cystic fibrosis trans membrane genotyping (CFTR) with two disease causing mutations
- pancreatic exocrine insufficiency
- ages 16 years and older
- clinically stable, defined as no changes in medical regimen (including medications) for at least 21 days prior to study visit
- baseline FEV1% predicted ≥40% where baseline is defined as the average of the best FEV1% for each quarter of the calendar year
- participation in the Cystic Fibrosis Foundation (CFF) Patient Registry
Longitudinal study inclusion:
CF participants who have normal glucose tolerance results after their initial study oral glucose tolerance test (OGTT).
Healthy controls inclusion criteria:
- male or female ages 16 years and older
- clinically stable. Healthy controls will be recruited who are similar in age, gender, and BMI as the participants with CF.
Exclusion Criteria:
CF exclusion criteria:
- diagnosis of CF-related diabetes (CFRD)
- nocturnal tube feeds
- life expectancy <6 months
- history of or on waiting list for lung transplant
- un-removable metal that is incompatible with MRI
- inability or unwillingness to perform major study activities (OGTT, DEXA, MRI) due to claustrophobia, fear of blood draw, or other reasons
- current pregnancy or lactation
- inability to provide informed consent or assent
Healthy controls exclusion criteria:
- malignant neoplasm (other than localized basal cell cancer of the skin) during the previous 5 years
- respiratory (including asthma), endocrine (including diabetes), autoimmune, or other chronic disease
- HIV or other chronic infection
- current use of any medications to treat an acute or chronic disease or illness
- acute illness within the past 3 weeks
- intravenous or oral antibiotics or use of systemic corticosteroids within the past 3 weeks
- inability or unwillingness to perform major study activities due to claustrophobia, fear of blood draw, or other reasons
- current pregnancy or lactation
- inability to provide informed consent or assent.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Subjects with Cystic Fibrosis
n=60 patients with CF ages 16-30
|
Healthy Controls
n=30 healthy controls matched to participants with CF for age, sex, BMI, and race.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Visceral Adipose Tissue volume (VAT) by Magnetic Resonance Imaging (MRI)
Time Frame: Baseline, 1 year, 2 year
|
Body fat distribution and body composition in 60 individuals with Cystic Fibrosis (CF) and 30 matched, healthy control will be assessed by Magnetic Resonance Imaging (MRI)
|
Baseline, 1 year, 2 year
|
Change in Disposition Index
Time Frame: Baseline, 1 year, 2 year
|
The disposition index (DI) is a measure of the ability of B-cells to compensate for insulin resistance. A lower DI indicates a loss of B-cell function, which means decreased pancreatic function. The disposition index will be assessed with an oral glucose tolerance test (OGTT) and mathematical modeling of the C-peptide and insulin response to glucose. This study seeks to determine if glucose intolerance is associated with body composition and fat distribution in CF subjects. |
Baseline, 1 year, 2 year
|
Change in Forced Expiratory Volume in the first second (FEV1%)
Time Frame: Baseline, 1 year, 2 year
|
Clinical spirometry is a test of lung function that will be used to assess the progression of lung disease with the baseline Forced Expiratory Volume (FEV%) predicted within the past year.
Baseline is defined as the average of the best FEV1% for each quarter of the calendar year.
FEV1% predicted is a method of determining the severity of pulmonary disease and declines as disease severity increases.
|
Baseline, 1 year, 2 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Pancreatic lipid
Time Frame: Baseline, 1 year, 2 year
|
Pancreatic lipid contributes to the Visceral Adipose Tissue volume (VAT) and it will me measured with the magnetic resonance imaging (MRI). Participants will lay in the supine position for approximately 30 minutes while in the MRI scanner, and images of the abdominal area (L1-L5 vertebrae) and thigh area will be obtained. Images will later be analyzed for quantification of VAT volume and lipid content of pancreas will be analyzed |
Baseline, 1 year, 2 year
|
Change in Hepatic lipid
Time Frame: Baseline, 1 year, 2 year
|
Hepatic lipid contributes to the Visceral Adipose Tissue volume (VAT) and it will me measured with the MRI. Participants will lay in the supine position for approximately 30 minutes while in the MRI scanner, and images of the abdominal area (L1-L5 vertebrae) and thigh area will be obtained. Images will later be analyzed for quantification of VAT volume and lipid content of liver will be analyzed |
Baseline, 1 year, 2 year
|
Change in Thigh perimuscular adipose tissue (PMAT)
Time Frame: Baseline, 1 year, 2 year
|
Thigh PMAT contributes to the VAT and it will me measured with the MRI.
Participants will lay in the supine position for approximately 30 minutes while in the MRI scanner, and images of the abdominal area (L1-L5 vertebrae) and thigh area will be obtained.
Images will later be analyzed for quantification of VAT volume and Thigh PMAT
|
Baseline, 1 year, 2 year
|
Change in Body Composition Analysis
Time Frame: Baseline, 1 year, 2 year
|
Dual-energy X-ray absorptiometry (DEXA) is an imaging technique that provides whole body and regional estimates of the three main body components: fat, lean soft tissues and bone mineral mass.
|
Baseline, 1 year, 2 year
|
Change in Insulin secretion
Time Frame: Baseline, 1 year, 2 year
|
Insulin secretion measures the total beta cell response (PhiTot), and will be assessed with an oral glucose tolerance test (OGTT). Fasted blood samples will be drawn 30 minutes and 15 minutes before the initiation of glucose consumption. At time "zero", an oral glucose solution at the dose of 1.75 gm/kg to a maximum of 75 gms will be provided and consumed within 5 minutes of administration. Subsequent blood samples will be drawn at 10, 20, 30, 60, 90, and 120 min following initiation of glucose ingestion. Decreased insulin secretion has been associated with lower B-cell function. |
Baseline, 1 year, 2 year
|
Change in Whole body insulin sensitivity index (WBISI)
Time Frame: Baseline, 1 year, 2 year
|
Insulin sensitivity describes how sensitive the body is to the effects of insulin. Whole body insulin sensitivity index (WBISI) is derived from glucose and insulin levels from the full length of the OGTT. The index is calculated using a formula. Decreased insulin sensitivity index is associated with more advanced CF disease. |
Baseline, 1 year, 2 year
|
Annual rate of Forced Expiratory Volume in the first second (FEV1%) decline
Time Frame: Baseline, 1 year, 2 year
|
FEV1 is the maximal amount of air you can forcefully exhale in one second. It is then converted to a percentage of normal, based on your height, weight, and race. It is assessed when doing the spirometry. |
Baseline, 1 year, 2 year
|
Number of pulmonary exacerbations needing intravenous (IV) antibiotics within previous five years
Time Frame: Baseline
|
Number of pulmonary exacerbations needing intravenous (IV) antibiotics within previous five years will be recorded.
|
Baseline
|
Number of Perceived respiratory symptoms measured with the Cystic Fibrosis Questionnaire-Revised (CFQ-R)
Time Frame: Baseline, 1 year, 2 year
|
The Cystic Fibrosis Questionnaire-Revised (CFQ-R) is a disease-specific instrument, designed to measure impact on overall health, daily life, perceived well-being and symptoms. Scores range from 0 to 100, with higher scores indicating better health. |
Baseline, 1 year, 2 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jessica A Alvarez, PhD, RD, Emory University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00110358
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Researchers who provide a methodologically sound proposal that is approved by all primary study co-investigators.
Types of analyses: To achieve the aims in the approved proposal and for individual participant data-meta analysis.
Proposals should be directed to Dr. Alvarez at jessica.alvarez@emory.edu
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystic Fibrosis
-
Hospital de Clinicas de Porto AlegreUnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With ExacerbationBrazil
-
University of Colorado, DenverCystic Fibrosis FoundationTerminatedCystic Fibrosis-related Diabetes | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in ChildrenUnited States
-
Royal College of Surgeons, IrelandThe Hospital for Sick Children; Imperial College London; Erasmus Medical Center; University College Dublin and other collaboratorsActive, not recruitingCystic Fibrosis | Adherence, Medication | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in Children | Cystic Fibrosis Liver DiseaseUnited Kingdom, Ireland
-
Herlev and Gentofte HospitalCopenhagen University Hospital, DenmarkActive, not recruitingMyocardial Infarction | Heart Diseases | Heart Failure | Stroke | Cystic Fibrosis | Heart Failure, Diastolic | Heart Failure, Systolic | Left Ventricular Dysfunction | Cystic Fibrosis-related Diabetes | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of Pancreas | Cystic Fibrosis, Pulmonary | Cystic...Denmark
-
The Hospital for Sick ChildrenCanadian Cystic Fibrosis FoundationActive, not recruitingCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in ChildrenCanada
-
Arrowhead PharmaceuticalsTerminatedCystic Fibrosis, PulmonaryAustralia, New Zealand
-
AzurRx SASCompletedCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of PancreasTurkey, Hungary
-
Dartmouth-Hitchcock Medical CenterTrustees of Dartmouth CollegeWithdrawnCystic Fibrosis-related Diabetes | Cystic Fibrosis Liver Disease | CF - Cystic FibrosisUnited States
-
University Hospital, BordeauxCompleted
-
University of PortsmouthUniversity Hospital Southampton NHS Foundation Trust; Loughborough University; Queen Alexandra HospitalTerminated